| How to build and interpret a nomogram for cancer prognosis A Iasonos, D Schrag, GV Raj, KS Panageas Journal of clinical oncology 26 (8), 1364-1370, 2008 | 2744 | 2008 |
| Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial E Basch, AM Deal, MG Kris, HI Scher, CA Hudis, P Sabbatini, L Rogak, ... Journal of Clinical Oncology 34 (6), 557-565, 2016 | 2378 | 2016 |
| Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment E Basch, AM Deal, AC Dueck, HI Scher, MG Kris, C Hudis, D Schrag Jama 318 (2), 197-198, 2017 | 2047 | 2017 |
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population JL Warren, CN Klabunde, D Schrag, PB Bach, GF Riley Medical care 40 (8), IV-3-IV-18, 2002 | 2004 | 2002 |
| American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer AB Benson III, D Schrag, MR Somerfield, AM Cohen, AT Figueredo, ... Journal of clinical oncology 22 (16), 3408-3419, 2004 | 1798 | 2004 |
| Diagnosis and treatment of metastatic colorectal cancer: a review LH Biller, D Schrag Jama 325 (7), 669-685, 2021 | 1663 | 2021 |
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry KY Chung, J Shia, NE Kemeny, M Shah, GK Schwartz, A Tse, A Hamilton, ... Journal of clinical oncology 23 (9), 1803-1810, 2005 | 1428 | 2005 |
| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1420 | 2017 |
| Patients' expectations about effects of chemotherapy for advanced cancer JC Weeks, PJ Catalano, A Cronin, MD Finkelman, JW Mack, NL Keating, ... New England Journal of Medicine 367 (17), 1616-1625, 2012 | 1346 | 2012 |
| Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment BK Edwards, ML Brown, PA Wingo, HL Howe, E Ward, LAG Ries, ... Journal of the National Cancer Institute 97 (19), 1407-1427, 2005 | 1266 | 2005 |
| The financial toxicity of cancer treatment: a pilot study assessing out‐of‐pocket expenses and the insured cancer patient's experience SY Zafar, JM Peppercorn, D Schrag, DH Taylor, AM Goetzinger, X Zhong, ... The oncologist 18 (4), 381-390, 2013 | 1133 | 2013 |
| Primary care physicians who treat blacks and whites PB Bach, HH Pham, D Schrag, RC Tate, JL Hargraves New England Journal of Medicine 351 (6), 575-584, 2004 | 1111 | 2004 |
| American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options LE Schnipper, NE Davidson, DS Wollins, C Tyne, DW Blayney, D Blum, ... Journal of Clinical Oncology 33 (23), 2563-2577, 2015 | 1022 | 2015 |
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ... Journal of Clinical Oncology 28 (22), 3617-3622, 2010 | 1008 | 2010 |
| Variations in morbidity after radical prostatectomy CB Begg, ER Riedel, PB Bach, MW Kattan, D Schrag, JL Warren, ... New England Journal of Medicine 346 (15), 1138-1144, 2002 | 1006 | 2002 |
| Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) E Basch, BB Reeve, SA Mitchell, SB Clauser, LM Minasian, AC Dueck, ... Journal of the National Cancer Institute 106 (9), dju244, 2014 | 960 | 2014 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 872 | 2017 |
| The influence of hospital volume on survival after resection for lung cancer PB Bach, LD Cramer, D Schrag, RJ Downey, SE Gelfand, CB Begg New England Journal of Medicine 345 (3), 181-188, 2001 | 787 | 2001 |
| Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) AC Dueck, TR Mendoza, SA Mitchell, BB Reeve, KM Castro, LJ Rogak, ... JAMA oncology 1 (8), 1051-1059, 2015 | 757 | 2015 |
| American Society of Clinical Oncology guidance statement: the cost of cancer care NJ Meropol, D Schrag, TJ Smith, TM Mulvey, RM Langdon Jr, D Blum, ... Journal of Clinical Oncology 27 (23), 3868-3874, 2009 | 701 | 2009 |
